Keyword: NEA

Takeda and NEA back $39M series A for GI biotech OrphoMed

OrphoMed gained a $39 million early funding boost from a Japanese big pharma and a host of VCs as it looks to push on with work on its leading med for forms of irritable bowel syndrome that it hopes can have a better safety profile than those meds on the market.